Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

Strategic highlights ? solid progress on both strategic and operational priorities  Increased momentum in programmable networks, mobile network contract wins in multiple markets.  Global supply of ...

With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...

However, the market is expected to grow significantly between 2022 and 2032, with a projected growth rate of 7%, which is ...

According to the new US Egg Packaging, demand for egg cartons is projected to increase 2.0% annually to $922 million in 2028, ...

The global kinase inhibitor in autoimmune diseases market is projected to grow steadily over the next decade, according to a ...

We recently published a list of 8 High Growth UK Stocks to Invest In. In this article, we are going to take a look at where ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...